Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Tocris Bioscience™ ARCC 4

Potent and selective androgen receptor PROTAC™

Manufacturer:  Tocris Bioscience™ 7254/5

Catalog No. 72-545


Add to cart
This item is not returnable. View return policy

Description

Description

ARCC 4 is a potent and selective androgen receptor (AR) PROTAC™ Degrader (DC50 = 5 nM). Comprises an androgen receptor antagonist, enzalutamide, joined by a linker to a VHL E3 ligase ligand. Brings about degradation of ARs in VCaP and LNCaP prostate cancer cell lines (Dmax = 98% at 12h) in a proteasome-dependent manner, and inhibits cell proliferation. Also degrades clinically relevant AR mutants expressed in HEK293T cells. Exhibits no significant effect on glucocorticoid, estrogen or progesterone receptors at concentrations inducing AR degradation.

ARCC 4 negative control (Cat. No. 7255) also available.

PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Specifications

Specifications

(2 S,4 R)-1-(-2-(2-(4-((4 '-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-[1,1 '-biphenyl]-4-yl)oxy)butoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxami
Active Degraders
1973403-00-7
0.98
C53H56F3N7O7S2
5 mg
Safety and Handling

Safety and Handling

Recommended Storage : Store at -20°C

SDS
Documents
Product Certifications
Promotions

Promotions

Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit